PMCB YT .png
PharmaCyte Biotech Will Have All the Protection It Needs for Pancreatic Cancer Treatment Upon Marketing Approval
February 04, 2020 09:00 ET | PharmaCyte Biotech
NEW YORK, NY, Feb. 04, 2020 (GLOBE NEWSWIRE) -- PharmaCyte Biotech (OTCQB: PMCB) is about to embark upon a planned U.S. FDA Phase 2b clinical trial to treat locally advanced, inoperable pancreatic...
PMCB YT .png
PharmaCyte Biotech’s Pancreatic Cancer Therapy Passes Critical FDA-Required Tests as Countdown to IND Submission Begins
January 27, 2020 09:00 ET | PharmaCyte Biotech
NEW YORK, NY, Jan. 27, 2020 (GLOBE NEWSWIRE) -- PharmaCyte Biotech (OTCQB: PMCB) announced that its clinical trial product, which will be employed during the company’s upcoming Phase 2b clinical...
PMCB YT .png
PharmaCyte Biotech Addressing Unmet Need in Patients with LAPC as Pancreatic Cancer 5-Year Survival Rate Increases to 10%
January 14, 2020 09:00 ET | PharmaCyte Biotech
NEW YORK, NY, Jan. 14, 2020 (GLOBE NEWSWIRE) -- This month the American Cancer Society announced that for the first time ever, the 5-year survival rate for pancreatic cancer has reached double...
PMCB YT .png
PharmaCyte Biotech Set to Reach Three Major Milestones in 2020
January 06, 2020 09:00 ET | PharmaCyte Biotech
NEW YORK, NY, Jan. 06, 2020 (GLOBE NEWSWIRE) -- PharmaCyte Biotech’s (OTCQB: PMCB) shareholders should expect 2020 to be the year that ushers in a host of much-anticipated milestones.  This year the...
PMCB YT .png
PharmaCyte Biotech Finalizes Pancreatic Cancer Treatment for U.S. FDA Approval to Begin Clinical Trial
December 11, 2019 09:00 ET | PharmaCyte Biotech
NEW YORK, NY, Dec. 11, 2019 (GLOBE NEWSWIRE) -- PharmaCyte Biotech (OTCQB: PMCB) has a clinical trial product, a clinical trial protocol, including a clinical trial design, a Principal Investigator,...
PMCB YT .png
PharmaCyte Biotech Nearing Major Milestone—An Open IND with the FDA
February 04, 2019 09:20 ET | PharmaCyte Biotech
NEW YORK, NY, Feb. 04, 2019 (GLOBE NEWSWIRE) -- Clinical stage biotechnology company PharmaCyte Biotech (OTCQB: PMCB) is now closer than ever to reaching what would be a monumental milestone in the...
PMCB YT .png
World-Renowned Oncologist Bullish on Potential of PharmaCyte’s Technology, Clinical Trial in Pancreatic Cancer
January 23, 2019 09:25 ET | PharmaCyte Biotech
NEW YORK, NY, Jan. 23, 2019 (GLOBE NEWSWIRE) -- With PharmaCyte Biotech, Inc.’s (OTCQB: PMCB) naming of Medpace, Inc., a global full-service clinical contract research organization (CRO) to conduct...
PharmaCyte Closing in on Submission of Crucial Investigational New Drug Application to Begin Clinical Trial in Pancreatic Cancer
May 21, 2018 09:20 ET | PharmaCyte Biotech
NEW YORK, NY, May 21, 2018 (GLOBE NEWSWIRE) -- PharmaCyte Biotech (OTCQB: PMCB) has reached the proverbial “home stretch” regarding its efforts to submit an Investigational New Drug Application...
First Ever Cannabis-Based ETF to Include PharmaCyte Biotech, Abbott Laboratories, and GW Pharmaceuticals
February 23, 2017 09:15 ET | PharmaCyte Biotech, Inc.
NEW YORK, NY--(Marketwired - February 23, 2017) - PharmaCyte Biotech (OTCQB: PMCB) will join GW Pharmaceuticals, Abbott Laboratories and 66 other publicly traded companies in what could be the first...
PharmaCyte Going Head to Head with Eli Lilly's Pancreatic Cancer Drug in New Clinical Trial
January 24, 2017 09:10 ET | PharmaCyte Biotech, Inc.
NEW YORK, NY--(Marketwired - January 24, 2017) - Ten years ago the National Cancer Institute (NCI) recognized the rise in pancreatic cancer deaths and called for the development of better treatments....